pulmicort and xylometazoline

Recent reports have shown that, although rare, findings of mucosal ulcers and perforations of the nasal septum in some cases may be associated with the use of topical nasal glucocorticosteroids (GCS). It can been speculated that, a reduction in septal mucosal blood flow causing ischemia may eventually induce septal perforations.. To evaluate whether a single dose of a potent nasal GCS given in a clinically recommended dose may acutely reduce the mucosal blood flow on the nasal septum.. Six healthy subjects received in a randomised double blind placebo controlled crossover procedure one dose of 64 micrograms budesonide aqueous nasal spray (Rhinocort aqua, AstraZeneca R&D, Lund, Sweden) and placebo. One dose was delivered into each nasal cavity by means of a pump spray. As a positive control 140 micrograms of xylometazoline (Nezeril, AstraZeneca R&D, Lund, Sweden) was sprayed in the same way, but in an open fashion. A wash-out period of at least 3 days followed each session. Blood flow was measured on the nasal septum with Laser Doppler flowmetry up to 20 min after administration.. Budesonide did not affect the nasal septal mucosal blood flow as compared to placebo, but xylometazoline reduced the septal mucosal blood flow by 60.9 +/- 7.1% measured from baseline values.. A single dose of intranasal budesonide aqueous nasal spray has no acute effects on nasal septal mucosal blood flow.

Topics: Administration, Intranasal; Adult; Analysis of Variance; Anti-Inflammatory Agents; Budesonide; Cross-Over Studies; Double-Blind Method; Female; Glucocorticoids; Humans; Imidazoles; Laser-Doppler Flowmetry; Male; Nasal Decongestants; Nasal Mucosa; Nasal Septum; Regional Blood Flow

Previous rhinomanometry studies have shown significant long-term variability of the nasal airway resistance and questioned the clinical validity of rhinomanometry.. Could treatment with a topical glucocorticoid, budesonide, influence the long-term variability of active anterior rhinomanometry?. Eight healthy volunteers participated in an unblinded controlled trial without, and later with, nasal budesonide once a day for 5 months. Their nasal airway resistance was measured every two weeks with active anterior rhinomanometry before and after decongestion with xylometazoline hydrochloride. In addition, subjective nasal obstruction was evaluated on a Visual Analogue Scale before each measurement. The participants had a year earlier been investigated with rhinomanometry every two weeks during 5 months but without budesonide treatment. We compared the variability of nasal airway resistance during the two periods with and without treatment with topical budesonide.. Budesonide significantly reduced mean nasal airway resistance and the standard deviation of the mean after decongestion for 6 of 8 participants. The mean reduction of the nasal airway resistance was 40% for the decongested nasal cavity compared to the period without treatment with nasal budesonide. Subjective nasal obstruction assessed by Visual Analogue Scale was reduced in 3 of the 8 participants.. The variability of nasal airway resistance was significantly reduced by treatment with topical budesonide for 6 out of 8 healthy volunteers participating in an unblinded repeated 5 month trial where the participants served as their own controls.

Topics: Airway Resistance; Budesonide; Glucocorticoids; Humans; Imidazoles; Nasal Cavity; Nasal Obstruction; Rhinomanometry

This study revealed that the nasal topical drops, which could be purchased without a proper prescription, should not be used randomly and non-selectively.. To investigate the effect of nasal drops and sprays on the nasal air flow and mucociliary transport time (MTT) in healthy volunteers with no septal deviation and no history of frequent upper respiratory infection.. Saline, fluticasone propionate drops and sprays, mometasone furoate, budesonide, xylometasoline chloride, fusafungine spray, Ringer's lactate and sea water were selected as the agents to be investigated. Volunteers were subdivided into two subgroups according to their rhinomanometric scores: group 1 consisted of subjects with nasal respiration > or =500 ml at 150 daPa and group 2 consisted of those with nasal air flow <500 ml.. No statistically significant difference was found among the effects of these agents on MTT in group 1. In group 2, xylometasoline chloride, fluticasone propionate spray and sea water sprays prolonged the MTT. When the rhinomanometric scores at 150 daPa were assessed, use of xylometasoline chloride, fluticasone propionate drops, budesonide, fusafungine, sea water and Ringer's lactate were found to diminish the nasal air flow with respect to normal values in group 1. In group 2, no significant difference was noticed between normal values and values acquired after use of nasal drops. Comparing the same agents, we did not find a significant difference between groups 1 and 2 regarding MTT and nasal air flow.

Topics: Administration, Intranasal; Adult; Aerosols; Androstadienes; Anti-Bacterial Agents; Anti-Inflammatory Agents; Budesonide; Depsipeptides; Female; Fluticasone; Fusarium; Humans; Imidazoles; Isotonic Solutions; Male; Mometasone Furoate; Mucociliary Clearance; Nasal Decongestants; Nasal Mucosa; Nonprescription Drugs; Pregnadienediols; Pulmonary Ventilation; Rhinomanometry; Ringer's Lactate; Seawater; Sodium Chloride; Solutions; Young Adult